Compare SLVM & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLVM | REPL |
|---|---|---|
| Founded | 1898 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2021 | 2018 |
| Metric | SLVM | REPL |
|---|---|---|
| Price | $34.79 | $12.80 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $54.00 | $5.67 |
| AVG Volume (30 Days) | 198.2K | ★ 2.4M |
| Earning Date | 05-08-2026 | 05-21-2026 |
| Dividend Yield | ★ 4.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,351,000,000.00 | N/A |
| Revenue This Year | $0.93 | N/A |
| Revenue Next Year | $1.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $34.25 | $1.50 |
| 52 Week High | $56.80 | $16.33 |
| Indicator | SLVM | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 41.07 | 43.79 |
| Support Level | $34.25 | $6.81 |
| Resistance Level | $40.13 | $16.02 |
| Average True Range (ATR) | 1.16 | 0.79 |
| MACD | -0.03 | -0.47 |
| Stochastic Oscillator | 31.45 | 18.07 |
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.